Background

COVID-19-related pleural effusions are frequently described during the ongoing pandemic.

Objectives

We described the incidence, characteristics, and outcomes of COVID-19-related pleural effusions based on the current evidence available in the literature.

Methods

We searched MEDLINE, Pubmed, and Google Scholar databases using keywords of “coronavirus disease 2019 (COVID-19),” “severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),” “pleural effusion,” “pleural fluid,” and “pleura” from January 1st, 2020 to January 31st, 2021.

Results

The incidence of pleural effusions was low at 7.3% among the 47 observational studies. Pleural effusions were commonly observed in critically ill patients and had Multisystem Inflammatory Syndrome (MIS). COVID-19-related pleural effusions were identified 5–7 days and 11 days, after hospital admission and onset of COVD-19 symptoms. The characteristic findings of pleural fluid were exudative, lymphocytic or neutrophilic-predominant pleural fluid with markedly elevated lactate dehydrogenase (LDH) levels and pleural fluid to serum LDH ratio.

Conclusion

A well-designed study is required to assess the significance of COVID-19-related pleural effusions during this current pandemic.

中文翻译：

---

COVID-19 肺炎胸腔积液的发生率：最新综述

背景

在持续的大流行期间经常描述与 COVID-19 相关的胸腔积液。

目标

我们根据现有的文献证据描述了 COVID-19 相关胸腔积液的发生率、特征和结果。

方法

我们使用“2019 冠状病毒病 (COVID-19)”、“严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2)”、“胸腔积液”、“胸腔积液”等关键词搜索了 MEDLINE、Pubmed 和 Google Scholar 数据库和“胸膜”从2020年1月1日到2021年1月31日。

结果

在 47 项观察性研究中，胸腔积液的发生率较低，为 7.3%。胸腔积液常见于重症患者，并患有多系统炎症综合征 (MIS)。在入院和出现 COVD-19 症状后的 5-7 天和 11 天发现了与 COVID-19 相关的胸腔积液。胸水的特征性发现是渗出性、淋巴细胞或中性粒细胞为主的胸水，乳酸脱氢酶 (LDH) 水平和胸水与血清 LDH 比率显着升高。

结论

需要一项精心设计的研究来评估当前大流行期间与 COVID-19 相关的胸腔积液的重要性。